WhiteOak Capital Pharma and Healthcare Fund

A Sectoral/Thematic Fund scheme from WhiteOak Capital Mutual Fund. Figures below are for the Direct · Growth plan (ISIN INF03VN01886).

NAV ₹18.3120 on 16 November 2026.

Expense ratio

Total expense ratio 1.07% a year for the Direct · Growth plan, as AMFI published it on 29 October 2026: base expense ratio 0.54%, brokerage 0.12%, transaction costs 0.01%, statutory levies including GST 0.40%.

Returns and risk

PeriodReturn a yearVolatilityWorst fallSharpeSortino
1 year26.1%14.2%-9.8%1.341.44

Too little NAV history for the 3, 5, 10-year figures.

Not ranked in its category: too few comparable funds have the history to rank against.

Largest holdings

Top 10 (September 2026 disclosure). Company shares make up 90.7% of the portfolio.

  1. Divi's Laboratories Limited — 8.36%
  2. Sun Pharmaceutical Industries Limited — 7.11%
  3. Torrent Pharmaceuticals Limited — 6.26%
  4. Clearing Corporation of India Ltd (cash (TREPS)) — 5.55%
  5. Laurus Labs Limited — 3.91%
  6. Apollo Hospitals Enterprise Limited — 3.75%
  7. Cipla Limited — 3.68%
  8. Sai Life Sciences Limited — 3.28%
  9. IPCA Laboratories Limited — 2.88%
  10. Zydus Lifesciences Limited — 2.81%

Plans

Other funds in Sectoral/Thematic Fund

All 257 funds in Sectoral/Thematic Fund · Compare this fund with another

Past returns are history, not a forecast. XIRRO describes funds and portfolios; it is information, not investment advice.